<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628805</url>
  </required_header>
  <id_info>
    <org_study_id>2022-0747</org_study_id>
    <nct_id>NCT05628805</nct_id>
  </id_info>
  <brief_title>Theta Burst Stimulation to Improve Inhibitory Motor Physiology in Tourette Syndrome</brief_title>
  <official_title>Theta Burst Stimulation to Improve Inhibitory Motor Physiology in Tourette Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tourette Association of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decades of Tourette Syndrome (TS) neuroimaging research has revealed abnormal cortical and&#xD;
      subcortical motor system network, hypothesized to result from maladaptive plasticity.&#xD;
      Repetitive transcranial magnetic stimulation ([r]TMS) is a promising technology that utilizes&#xD;
      the concept of neuroplasticity to modulate brain circuits. TMS modulation has the distinct&#xD;
      advantage in terms of its non-invasive nature. Furthermore, unique stimulation paradigms such&#xD;
      as intermittent theta-burst repetitive TMS (iTBS) allows for short stimulation time (&lt;3 min).&#xD;
&#xD;
      Using a sham-controlled protocol, the investigators propose modulating pre-SMA output using&#xD;
      iTBS, based on our prior data of abnormal pre-SMA-mediated motor system regulation.&#xD;
      hypothesize pre-SMA modulation results in increased pre-SMA-mediated motor inhibition.&#xD;
      Enhancing these inhibitory measures with pre-SMA-iTBS provides the basis for improving&#xD;
      inhibitory function in TS patients, leading to our long-term goal of neuro-stimulation to&#xD;
      achieve clinical tic reduction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in cortical silent period (cSP)</measure>
    <time_frame>On the same day, we will assess change in cSP prior to active (or sham) iTBS treatment and immediately after iTBS treatment</time_frame>
    <description>cSP is a biomarker of inhibitory motor physiology</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tourette Syndrome</condition>
  <condition>Tourette Syndrome in Children</condition>
  <condition>Tourette Syndrome in Adolescence</condition>
  <condition>Tourette Syndrome, Modifier of</condition>
  <arm_group>
    <arm_group_label>iTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham iTBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Each participant will have two separate study days in the TMS lab. On one day, the participant will receive active pre-SMA iTBS. On the other day, the patricipant will receive sham pre-SMA iTBS. The order that active versus sham is given will be randomized and the participant will be blinded. After each iTBS session, blinding assessment will be performed. To avoid contamination of results, a minimum of 5 days between study days will be required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTBS</intervention_name>
    <description>intermittent theta burst stimulation with TMS</description>
    <arm_group_label>Sham iTBS</arm_group_label>
    <arm_group_label>iTBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants of any sex, race, or ethnicity meeting all criteria listed below will be&#xD;
        included in the study:&#xD;
&#xD;
          1. Aged 10-21 years&#xD;
&#xD;
          2. Fluent in English&#xD;
&#xD;
          3. DSM-5 diagnosis of TS, confirmed by the clinical team&#xD;
&#xD;
          4. Able to participate in the informed consent process, provide voluntary informed&#xD;
             consent/assent and provide a spontaneous narrative description of the key elements of&#xD;
             the study.&#xD;
&#xD;
          5. Clinical stability: determined by a physician, no switch of psychotropic medications&#xD;
             or increase in dosage in the last 14 days from TMS treatment start; no change in other&#xD;
             therapeutic interventions in last 14 days from TMS treatment start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any neurodevelopmental, psychiatric condition other than TS, ADHD, or OCD, or mild&#xD;
             anxiety based on review of K-SADS. Note - if an exclusionary psychiatric diagnosis is&#xD;
             suspected based on K-SADS, the research physician will follow up with the parent and&#xD;
             referral will be made to psychology or psychiatry as appropriate.&#xD;
&#xD;
          2. Presence of metallic foreign bodies or implanted medical devices.&#xD;
&#xD;
          3. Not meeting inclusion criteria as described above&#xD;
&#xD;
          4. Non-fluency in English, as English is the language in the validated clinical&#xD;
             questionnaires, and the participant must be able to understand real-time instructions&#xD;
             from the study staff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Molly Griffith</last_name>
    <phone>513-636-9669</phone>
    <email>molly.griffith@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlee Migneault</last_name>
      <phone>513-803-5299</phone>
      <email>karlee.migneault@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Travis R Larsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve W Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernest V Pedapati, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald L Gilbert, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul S Horn, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 23, 2022</last_update_submitted>
  <last_update_submitted_qc>November 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Travis Larsh</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

